```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is read more a a valuable laboratory reagent extensively used in thrombosis research . This antibody fragment primarily targets the glycoprotein IIb/IIIa complex on platelets , preventing thrombus development. Consequently , it's commonly investigated as a tool to analyze the pathways underlying thrombosis and to determine the effectiveness of anticoagulant therapies. Supply is typically limited to academic settings.
```
The Abciximab Compound Research: Utilizing C7E3 and Compound 143653-53-6 in Studies
Ongoing studies into abciximab, a antiplatelet agent, frequently utilizes the monoclonal antigen C7E3 and the substance identified as 143653-53-6. These reagents are crucial for examining abciximab's biological activity, determining its effectiveness in various clinical settings, and exploring potential indicators of therapeutic success. Additional study leveraging these precise reagents is likely to generate valuable information for optimizing therapeutic strategies involving cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Scientific Avenues with the Drug Abciximab 143653-53-6 via C7E3
Recent work suggest that the drug (identified as 143653-53-6) holds significant scientific potential, particularly when combined with the antibody fragment. Early observations suggested that this combination could enhance therapeutic responses in various heart-related contexts. Further investigation is centered on defining the exact mechanism of effect between Abciximab and C7E3, including analysis of platelet clumping and arterial safeguarding.
- Future investigation work seek to maximize administration strategies.
- Animal models are are being utilized to additional assess such theories.
- Human assessments are required to thoroughly assess therapeutic effectiveness.
```
Abciximab (C7E3) for Research: Quality and Specifications (143653-53-6)
Researchers requiring this antibody for laboratory studies should rigorously evaluate quality and precise parameters . The compound is typically provided as a freeze-dried powder and comprehensive analytical documentation including verification by mass spectrometry , biological activity assays, and endotoxin level testing are available. Verify the supplier's documentation clearly states required ranges for related substances and conforms to established QC guidelines.
Research-Grade ReoPro Details & Supply
Acquiring research-grade Abciximab, specifically referencing the compound C7E3 and identified by the catalog number 143653-53-6, requires detailed consideration of its manufacturer. This antibody is frequently utilized in cell-based experiments, particularly those involving platelet clumping and occlusion. Existing suppliers offer this material in varying volumes, typically ranging from g to substantial commercial supplies. Please advise reviewing the certificate of testing to verify purity and appropriateness for your specific application . Additionally , check the shelf life date before obtaining to maintain ideal efficacy .
- Common Purity: >95%
- Storage Conditions: -20°C in controlled conditions
- Intended Purpose: Platelet Aggregation Blocking Studies